Both [18F]KL01040 and [18F]KL01007-pyridine-BF3 are promising for imaging PSMA expression with PET and Lys-ureido-Aad is a potential pharmacophore for further optimization of PSMA-targeting imaging and radiotherapeutic agents for characterization and treatment of angiogenesis-related diseases and PSMA-expressing cancers. Here, FOLH1 is linked to cancer.